Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 2/20 | 0.57 |
| ▸ | PLK1 | P53350 | 8/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL444328 | 0.77 | STAT3 (0.65) | STAT3ALDH1A1MEN1KMT2A | |
| SCHEMBL274052 | 0.77 | KMT2A (0.63) | TSHRSMN1; SMN2ALDH1A1POLBMEN1 | |
| SCHEMBL10244867 | 0.76 | CYP19A1 (0.50) | PRMT5TSHRSMN1; SMN2ALDH1A1USP2 | |
| SCHEMBL28247078 | 0.75 | PRMT5 (0.48) | PRMT5TSHRSTAT3SMN1; SMN2ALDH1A1 | |
| SCHEMBL4265604 | 0.71 | PLK1 (0.39) | PRMT5PLK1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL4518718 | 0.71 | STAT3 (0.42) | PRMT5STAT3SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL6707614 | 0.70 | HTR6 (0.60) | TSHRSMN1; SMN2ALDH1A1POLBMEN1 | |
| SCHEMBL5645566 | 0.69 | GPR84 (0.65) | TSHRALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL3219340 | 0.69 | PRMT5 (0.41) | PRMT5TSHRSTAT3SMN1; SMN2ALDH1A1 | |
| SCHEMBL18301164 | 0.69 | PRMT5 (0.41) | PRMT5TSHRSTAT3SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101687789-A | Novel inhibitors hepatitis c virus replication | INTERMUNE INC | 2010-03-31 | — | — | CN | disclosed |
| EP-2134683-A2 | NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION | Intermune, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2008100867-A2 | NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | PRMT5 822/4885PLK1 527/4885TSHR 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.